A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
Trial Registration: NCT03153036
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-06-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01296-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113183703891968 |
|---|---|
| author | Chandramouli Nagarajan Wei-Ying Jen Melissa Ooi Sanjay De Mel Cinnie Soekojo Sung Soo Yoon Melinda Tan Yunxin Chen Xinhua Li Yogesh Pokharkar Shi Ning Tham Nur Shahidah Binte Hashim Neha Awasthi Sarah M. Burkill Brian Durie Wee Joo Chng |
| author_facet | Chandramouli Nagarajan Wei-Ying Jen Melissa Ooi Sanjay De Mel Cinnie Soekojo Sung Soo Yoon Melinda Tan Yunxin Chen Xinhua Li Yogesh Pokharkar Shi Ning Tham Nur Shahidah Binte Hashim Neha Awasthi Sarah M. Burkill Brian Durie Wee Joo Chng |
| author_sort | Chandramouli Nagarajan |
| collection | DOAJ |
| description | Trial Registration: NCT03153036 |
| format | Article |
| id | doaj-art-8017fa0512a5488fb7ae7b356bfd271b |
| institution | OA Journals |
| issn | 2044-5385 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-8017fa0512a5488fb7ae7b356bfd271b2025-08-20T02:37:13ZengNature Publishing GroupBlood Cancer Journal2044-53852025-06-011511610.1038/s41408-025-01296-8A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)Chandramouli Nagarajan0Wei-Ying Jen1Melissa Ooi2Sanjay De Mel3Cinnie Soekojo4Sung Soo Yoon5Melinda Tan6Yunxin Chen7Xinhua Li8Yogesh Pokharkar9Shi Ning Tham10Nur Shahidah Binte Hashim11Neha Awasthi12Sarah M. Burkill13Brian Durie14Wee Joo Chng15Department of Haematology, Singapore General HospitalDepartment of Haematology-Oncology, National University Cancer InstituteDepartment of Haematology-Oncology, National University Cancer InstituteDepartment of Haematology-Oncology, National University Cancer InstituteDepartment of Haematology-Oncology, National University Cancer InstituteSeoul National University HospitalDepartment of Haematology, Singapore General HospitalDepartment of Haematology, Singapore General HospitalSingapore Clinical Research InstituteSingapore Clinical Research InstituteDepartment of Haematology, Singapore General HospitalDepartment of Haematology, Singapore General HospitalSingapore Clinical Research InstituteSingapore Clinical Research InstituteCedars-Sinai Medical CenterDepartment of Haematology-Oncology, National University Cancer InstituteTrial Registration: NCT03153036https://doi.org/10.1038/s41408-025-01296-8 |
| spellingShingle | Chandramouli Nagarajan Wei-Ying Jen Melissa Ooi Sanjay De Mel Cinnie Soekojo Sung Soo Yoon Melinda Tan Yunxin Chen Xinhua Li Yogesh Pokharkar Shi Ning Tham Nur Shahidah Binte Hashim Neha Awasthi Sarah M. Burkill Brian Durie Wee Joo Chng A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) Blood Cancer Journal |
| title | A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) |
| title_full | A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) |
| title_fullStr | A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) |
| title_full_unstemmed | A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) |
| title_short | A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) |
| title_sort | phase 2 study of daratumumab with thalidomide and dexamethasone in relapsed and or refractory myeloma rrmm |
| url | https://doi.org/10.1038/s41408-025-01296-8 |
| work_keys_str_mv | AT chandramoulinagarajan aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT weiyingjen aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT melissaooi aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT sanjaydemel aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT cinniesoekojo aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT sungsooyoon aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT melindatan aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT yunxinchen aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT xinhuali aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT yogeshpokharkar aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT shiningtham aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT nurshahidahbintehashim aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT nehaawasthi aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT sarahmburkill aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT briandurie aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT weejoochng aphase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT chandramoulinagarajan phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT weiyingjen phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT melissaooi phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT sanjaydemel phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT cinniesoekojo phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT sungsooyoon phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT melindatan phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT yunxinchen phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT xinhuali phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT yogeshpokharkar phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT shiningtham phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT nurshahidahbintehashim phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT nehaawasthi phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT sarahmburkill phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT briandurie phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm AT weejoochng phase2studyofdaratumumabwiththalidomideanddexamethasoneinrelapsedandorrefractorymyelomarrmm |